


- ❖ Management decisions can be challenging for both the patient and the healthcare professionals looking after them
- ❖ Increasing numbers of therapeutic options are available to clinicians and their use requires careful consideration of therapeutic benefit vs safety in pregnancy
- ❖ All decisions should be made with the patient at the center, the support of the multidisciplinary team and input from specialists in the field- a low threshold for seeking further expertise should exist

Safety of cancer treatments throughout gestation, the postpartum period and breastfeeding



- Surgery:**
- Considered safe throughout pregnancy but if possible preferred prior to 24 weeks gestation
 - Most anesthetic drugs are safe throughout gestation; suggest liaising with obstetric anaesthetist if any concerns
 - Fetal viability should be checked pre- and post- procedure
 - Immediate breast reconstruction using tissue expander can be performed after mastectomy, however, due to the physiological changes to the breast, delayed reconstruction should be considered

- Radiotherapy (RT):**
- Emergency RT may be considered in the 1st/2nd trimester - if beam can be angled distant to the pelvis (e.g. brain/ upper body bony metastasis) but only after discussion with a specialist
 - In all other cases RT should be postponed until after delivery, because of potential teratogenic and even lethal effects on the developing fetus. Breast-feeding should be avoided during RT, suckling may be difficult from the irradiated breast

- Chemotherapy:**
- Cytotoxic agents are teratogenic in the 1st trimester and thus contraindicated during this period
 - Anthracyclines, cyclophosphamide, and taxane-based (weekly paclitaxel) regimens can be used after the 1st trimester. There are also reports to support the addition of carboplatin-based regimens if required
 - Chemotherapy doses should be calculated using current as opposed to pre-pregnancy weight
 - Use published standard dose protocols (neither decrease/increase dose, do not increase treatment intervals)
 - A port-a-cath and other central venous access devices/peripherally inserted central catheter lines can be fitted as outside of pregnancy (using local anaesthetic, X-RAY and USS where indicated)
 - If possible, stop 3 weeks prior to delivery to allow the bone marrow to recover and prevent hematological complications during delivery. Leave a 14-day interval between last chemotherapy session and start of breastfeeding, if chemotherapy restarted stop breastfeeding

- Endocrine Therapy, Targeted Therapies, Immunotherapy:**
- Endocrine therapies are contraindicated in pregnancy (risk of malformation) and should be reserved for the postpartum period
 - Anti-HER2 agents, CDK4/6 inhibitors and anti-PD-(L)1 inhibitors are all contraindicated during pregnancy and should also be reserved for the postpartum period

- Supportive therapies:**
- Antiemetics (including ondansetron and metoclopramide) and proton pump inhibitors can safely be used throughout all gestations
 - Methylprednisolone, hydrocortisone and prednisolone are favored over dexamethasone
 - Neurokinin-1 inhibitors are contraindicated
 - G-CSFs should not be withheld if required

- Recommended contraception for those under investigation/postpartum:**
- Copper coil ✓
 - Nexplanon X
 - POP X
 - Mirena® X

- Obstetric Considerations:**
- Decisions regarding termination should be individualized with MDT input
 - Interpret 1st trimester screening with caution. Women with confirmed metastatic disease may have high serum β-hCG and should not have noninvasive prenatal testing (NIPT) as results can't be accurately interpreted
 - If exposed to preconception/1st trimester chemotherapy patient should have fetal medicine specialist scan
 - Vaginal delivery is not contraindicated
 - Discuss timing of delivery with MDT (aim 38-39 weeks)